Mike Hirschmann

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Their manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling them to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Their talented team is driven by a passion for science and compassion for patients.